Angående våre samarbeidspartnere så planlegger jo BioNTech en IPO på rundt 800 mill$ i nær fremtid. Dvs børsnotering, de er per i dag et privateid selskap.
Det vil jo gi BioNTech handlingsrom til å forfølge lovende prosjekter.
12 Likes
Nettopp!
Samarbeidet med BioNTech har vel vart i snart 3 år og gikk rett til invivo forsøk, så det er jo ikke umulig at det kommer litt fra den kanten snart.
Blir lettere å få innsyn i BioNTech når de blir børsnotert, så kanskje vi kan få litt mer informasjon gjennom den kanalen.
10 Likes
Mye spennende på gang i BioNTech:
It specializes in so-called messenger RNA (mRNA) molecules that instruct human cells to produce therapeutic proteins that trigger an immune response against cancer or infectious diseases.
Among its other areas of development are gene therapies and nano-particles for cancer immunotherapy.
Biotech investors Thomas and Andreas Struengmann, who sold their generic drugs business Hexal to Novartis in 2005, are majority shareholders in BioNTech, and other owners include German venture capital investor MIG Fonds.
Pfizer last year agreed to pay the German biotech firm up to $425 million in an alliance to develop more effective influenza shots and also acquired a smaller stake in the company.
BioNTech competes in the race for mRNA therapies with groups such as Massachusetts-based Moderna, whose market value peaked at $7.7 billion last month, as well as Belgium’s eTheRNA and domestic rival CureVac.
Apart from Pfizer, the emergent mRNA field has seen drugmakers such as AstraZeneca, Eli Lilly and Sanofi partner up with biotech firms.
BioNTech has previously attracted alliance partners including Roche’s Genentech, Eli Lilly, Sanofi, Genmab and Bayer Animal Health.
Så får vi bare håpe fimaNAC kan være en nøkkel på mRNA feltet…
8 Likes
PCIB’s resultater som av PW angis å være “veldig gode” (Q4) mht det som skal publiseres fra ultimovacs kan muligens spille en rolle når det kommer til interesse og partnerskap / utlisensiering av fimaVACC.
Når PCIB’s fimaVACC resultater publiseres og en også får publisert ultimovacs rapport så får en vel samtidig et eksempel på hvorledes fimaVACC bidrar i "terapautisk vaksine) (preklinisk)
Altså , muligens meget viktige data for BP som vurderer lisensiering av fimaVACC som er verdt mye tid og kapital tilnærmet helt gratis for PCIB , og , PW har guidet meget gode resultater fra ultimovacs samarbeidet under spørsmålsrunden etter Q4 rapporten.
8 Likes
8 Likes
Kristian Berg er viktig for PCIB
- Committees
- IPA BOARD OF DIRECTORS
5 Likes
9 Likes
Spennende!
Er vel ett kjempemarked hvis teknologien skulle vise seg å virke på blærekreft! 
3 Likes
Det er vel gammelt nytt at fimaCHEM funker sammen med Bleomycin i blærekreft modeller.
Finnes noe data fra dette i eldre Pcib presentasjoner mener jeg å huske.
4 Likes
Skal de ta noe av markedet til PHO?
1 Like
Kopierer denne hit også.
Dette var omtrent den wordingen vi håpte å se på fimavacc. Når blir det veldig spennende å se hva neste steg blir:
02/05-2019 18:57:43: (PCIB) PCI Biotech: Successful clinical translation of the fimaVacc technology
…
Vis børsmeldingen
Oslo (Norway), 2 May 2019 . PCI Biotech (OSE: PCIB), a cancer focused clinical-stage company developing innovative therapeutics that address significant unmet medical needs today announced that the final immune response results from the fima_Vacc_ Phase I study in healthy volunteers indicate a clear enhancement of both CD8 and CD4 T-cell responses and an improved CD8 T-cell functionality after vaccination at tolerable dose levels.
The interim clinical results previously reported that fima_Vacc_ may enhance overall T-cell responses, especially to the HPV peptide, which is much less immunogenic than the KLH protein. The final data confirms these results, showing a substantial increase in number of T-cell responders to the HPV peptides already after two vaccinations and a clear enhancement in the T-cell responses compared to the control group. The important CD8 responses are also more robust with fima_Vacc_ and exhibit increased functionality compared to control.
The overall clinical data cover more than 90 subjects providing clinical support of fima_Vacc_.s potential to enhance the cellular immune responses that are important for therapeutic effect of vaccines. This enhancement of cellular immune responses was seen at well tolerated fima_Vacc_ dose levels, with the tolerability of fima_Vacc_ also established across a wide range of doses. The analysis of overall T-cell responses has been done in collaboration with Oslo University Hospital, The Radium Hospital, while the analysis of CD8 T-cell responses has been done at Leiden University Medical Centre (LUMC).
Per Walday, CEO of PCI Biotech, said_: “Improving immunogenicity of vaccine candidates is a main priority in the immunotherapy industry. The encouraging results of the Phase I study provide proof of concept and efficacy in terms of optimal dosing of fimaVacc in humans as well as an overall characterization of tolerability, in keeping with the target objectives of the trial and paving the way for further development in a clinical setting.”_
The study was designed as an open-label, antigen-adjuvant controlled study with the objectives to determine immune responses, safety and tolerability of fima_Vacc_ in healthy volunteers. The study was performed with two model vaccines; a large immunogenic protein (KLH) and two smaller less immunogenic peptides (HPV). More than 90 subjects are included and recruitment is now stopped.
15 Likes
02/05-2019 18:57:43: (PCIB) PCI Biotech: Successful clinical translation of the fimaVacc technologysterk tekst
Det er bare å gratulere folkens 
10 Likes
Improved CD8 T-cell functionality. Blir spennende høre hva det innebærer.
1 Like
Se der ja!! Nå er det bare å lese og kose seg 
1 Like
Dett var dett? Hadde håpet på en presentasjon i det minste.
Så konklusjonen er egentlig at fimavacc fungerer?
1 Like
image
image.png
2048×1536 392 KB
Jubeldag! PCIB fortsetter, leverer igjen. Gratulerer til ansatte, ledelse, styret og advisory board! Lukter at ikke minst pasienter for nyte godt av teknologien.
Se beskrivelsen om Vacc teknologien i årsrapport og kvartalrapporter: virkelig imponerende hva som er oppnådd!!
About immunotherapy with the fimaVACC technology
The pharmaceutical industry has long recognised the potential of therapeutic cancer vaccination, i.e. vaccines that treat cancer by inducing or strengthening an immune response. Several companies have reported failed clinical studies in the past years, but the potential of combining vaccination with checkpoint inhibitors has triggered a renewed interest in therapeutic cancer vaccines. However, here are still important unsolved issues and improving the immunogenicity of vaccine candidates is a main priority in immunotherapy. PCI Biotech believes the fimaVacc technology may play an important role in solving this challenge.
Effective induction of cytotoxic T-cells is key to realise the huge potential of therapeutic cancer vaccination, but vaccines often fail to generate such responses. One of the most important reasons is probably insufficient delivery of vaccine antigens to the appropriate presentation pathway in immune cells. The fimaVacc technology may solve this challenge by effectively enhancing the vaccine presentation through this pathway.
Så leser du dagens børsmelding! Jadda! Provide proof of concept!!!
4 Likes
Kommer jo garantert mer informasjon om dette, jeg er nå fornøyd med at de bare fikk ut en børsmelding om ikke annet.
Nå er det ikke sånn at 90 meldte pasienter i et fase 1 studie nødvendigvis teller som noe “proof of concept” fra aksjemarkedets side.
5 Likes
I biotek og legemiddelbransjen og ikke minst investorer i bransjen sier proof Of concept innen et marked estimert til 7,5 milliarder usd A WHOLE LOT😄
2 Likes